BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
The company impresses investors, but money’s running short.
